Clinical trial

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

NCT06967103

Study summary

ClinicalTrials.gov

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention QL1706 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nab-PE Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-09-08

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

HR+/HER2- Breast Cancerunresolved

Interventions

QL1706DRUG

Nab-PEDRUG

Sponsors & collaborators

Henan Cancer Hospitallead sponsor

Mapped research locations

ZhengzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06967103 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.